Bacterial charity work leads to population-wide resistance.
Bacteria show remarkable adaptability in the face of antibiotic therapeutics. Resistance alleles in drug target-specific sites and general stress responses have been identified in individual end-point isolates. Less is known, however, about the population dynamics during the development of antibiotic-resistant strains. Here we follow a continuous culture of Escherichia coli facing increasing levels of antibiotic and show that the vast majority of isolates are less resistant than the population as a whole. We find that the few highly resistant mutants improve the survival of the population's less resistant constituents, in part by producing indole, a signalling molecule generated by actively growing, unstressed cells. We show, through transcriptional profiling, that indole serves to turn on drug efflux pumps and oxidative-stress protective mechanisms. The indole production comes at a fitness cost to the highly resistant isolates, and whole-genome sequencing reveals that this bacterial altruism is made possible by drug-resistance mutations unrelated to indole production. This work establishes a population-based resistance mechanism constituting a form of kin selection whereby a small number of resistant mutants can, at some cost to themselves, provide protection to other, more vulnerable, cells, enhancing the survival capacity of the overall population in stressful environments.
Lee
Henry H
HH
Howard Hughes Medical Institute, Center for BioDynamics, Boston, Massachusetts 02115, USA.
Molla
Michael N
MN
Cantor
Charles R
CR
Collins
James J
JJ
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development* / Q000378:metabolism; D020869:Gene Expression Profiling; D016680:Genome, Bacterial; D007211:Indoles / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability; D009154:Mutation; D009643:Norfloxacin / Q000378:metabolism / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D007211:Indoles; C030374:indole; D009643:Norfloxacin
Nat Rev Microbiol. 2006 Aug;4(8):597-607
16845430
Cell. 2007 Sep 7;130(5):797-810
17803904
Nat Genet. 2006 Dec;38(12):1406-12
17086184
Clin Microbiol Infect. 2007 Jan;13(1):5-18
17184282
Mol Syst Biol. 2006;2:2006.0008
16738554
FEMS Microbiol Rev. 2010 Jul;34(4):426-44
20070374
Genetics. 1996 May;143(1):15-26
8722758
Nature. 2008 Nov 6;456(7218):53-9
18987734
Antimicrob Agents Chemother. 1994 Aug;38(8):1773-9
7986007
Annu Rev Microbiol. 1996;50:625-43
8905093
Clin Infect Dis. 2003 Jan 15;36(Suppl 1):S11-23
12516026
PLoS One. 2009;4(4):e5043
19357784
Cell. 1997 Jul 11;90(1):43-53
9230301
J Bacteriol. 2006 Aug;188(16):5693-703
16885437
Antimicrob Agents Chemother. 2008 Sep;52(9):3052-60
18591276
Nat Methods. 2005 Dec;2(12):951-3
16299480
Nat Chem Biol. 2007 Sep;3(9):549-56
17710101
Genetics. 1998 Apr;148(4):1599-610
9560379
Cell. 2008 Nov 14;135(4):679-90
19013277
Mol Syst Biol. 2007;3:91
17353933
Biochem J. 1954 Jul;57(3):369-74
13181841
BMC Microbiol. 2007 May 18;7:42
17511876
Antimicrob Agents Chemother. 2001 May;45(5):1515-21
11302820
Science. 2003 May 30;300(5624):1404-9
12775833
Mol Cell. 2010 Feb 12;37(3):311-20
20159551
Trends Microbiol. 2010 Apr;18(4):149-56
20167493
Mol Microbiol. 2005 Feb;55(4):1113-26
15686558
Antimicrob Agents Chemother. 1999 Jan;43(1):62-6
9869566
Antimicrob Agents Chemother. 2006 Jun;50(6):2137-45
16723576
Bioinformatics. 2007 Nov 1;23(21):2897-902
17921172